Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26641238 | 0.85 | CRBN (0.54) | CRBNDDB1POLBDRD2 | |
| SCHEMBL24125402 | 0.85 | CRBN (0.59) | CRBNDDB1POLB | |
| SCHEMBL26641414 | 0.84 | SLC18A3 (0.54) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL27167725 | 0.84 | CARM1 (0.56) | CRBNDDB1POLB | |
| SCHEMBL26329328 | 0.83 | CRBN (0.46) | CRBNDDB1POLB | |
| SCHEMBL24873035 | 0.83 | CRBN (0.51) | CRBNDDB1POLBGSPT1DRD2 | |
| SCHEMBL24125612 | 0.83 | CRBN (0.54) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL31382219 | 0.83 | CRBN (0.54) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL24491304 | 0.82 | DDB1 (0.56) | CRBNDDB1 | |
| SCHEMBL26329288 | 0.82 | HTT (0.57) | CRBNDDB1POLBDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | RET, HRAS, RBX1 | CRBN 10/4885DDB1 397/4885POLB 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.